Developing new antibiotics using single-cell technology
Official title: A single-cell approach to developing non-traditional antibiotics
Funded at Princeton University · NIH-10923339 · Data updated 2026-11-12
This study is all about finding new antibiotics to help fight stubborn bacterial infections that don't respond to current treatments, using a special technique to see how bacteria and our cells interact, which could lead to better ways to tackle these tough germs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Princeton University NIH-funded |
| Lab location | 1 site (Princeton, UNITED STATES) |
| Project start | September 30, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $1,148,000 |
| NIH project number | 1DP1AI190418-01 |
| Project ID | NIH-10923339 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from bacterial infections, particularly those caused by antibiotic-resistant strains.
✕Less likely to help
Patients with viral infections or those who do not have bacterial infections may not benefit from this research.
What this research studies
This research focuses on creating innovative antibiotics to combat bacterial infections, particularly those that have developed resistance to existing treatments. By utilizing a cutting-edge single-cell RNA-sequencing method called M3-Seq, researchers can analyze the interactions between bacteria and host cells at an unprecedented level of detail. This approach allows for the simultaneous monitoring of gene expression in both bacterial and human cells, providing insights that traditional methods cannot achieve. The goal is to identify novel mechanisms of action for antibiotics that can effectively target resistant bacteria.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that effectively treat resistant bacterial infections.
How similar studies have gone: Other research has shown promise in using advanced sequencing technologies to understand bacterial resistance, indicating that this approach could yield significant advancements.
Where this research is happening
-
Princeton University
Princeton, United States Active
Researchers
- Principal investigator: Gitai, Zemer — Princeton University
- Study coordinator: Gitai, Zemer
Related research
Other NIH-funded projects on the same topics.
-
How neuropeptides could influence aging and Alzheimer’s risk
Researchers at Princeton are studying whether changing brain signaling chemicals called neuropeptides can extend healthy aging and reduce Alzheimer’s-related brain changes, with a focus on people at risk for Alzheimer’s disease dementia.
-
Sleep and aging brain resilience in a short-lived vertebrate model
A young-aged-friendly project explores how sleep quality affects brain health during aging, using a tiny, fast-lived fish model to understand Alzheimer’s-related changes.
-
How hepatitis C adapts to other species to help develop vaccines
Researchers are making a mouse-friendly version of hepatitis C so scientists can better test vaccines and understand the virus for people living with or at risk of hepatitis C.
-
Mapping how cells push and pull in living tissues
A science project at Princeton aims to map and control the forces between cells in 3D tissues to better understand cancer, development, and healing, with potential benefits for patients in the future.
-
Understanding how brain signals give rise to thinking using brain-wide recordings
Researchers at Princeton are developing new brain theories and computer tools to understand how complex neural signals relate to thinking and behavior.
-
Cancer metabolism revealed through mass spectrometry and isotope tracing
A scientist team at Princeton will study how cancer cells use nutrients by analyzing metabolites with advanced mass spectrometry and labeled tracers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.